Gerresheimer AGHAM:GXI +1.31%64 EBITDA Margin % is 13.38% as of Aug. 2025, which is 36% below its 10-year median of 20.77. GuruFocus rates HAM:GXI with a GF Score™ of 64/100 and a GF Value™ of €99.85 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Gerresheimer AG ranks better than 71.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gerresheimer AG's EBITDA for the
three
months ended in Aug. 2025 was €75 Mil. Gerresheimer AG's Revenue for the
three
months ended in Aug. 2025 was €561 Mil. Therefore, Gerresheimer AG's EBITDA margin for the quarter that ended in Aug. 2025 was 13.38%.
Gerresheimer AG (HAM:GXI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gerresheimer AG EBITDA Margin % Related Terms
Gerresheimer AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:GXI vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gerresheimer AG (HAM:GXI) has a EBITDA Margin % of 13.38% as of Aug. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gerresheimer AG and its competitors. This is 36% below median its historical median of 20.77. Over the past decade, Gerresheimer AG's EBITDA Margin % has ranged from 17.59 to 28.21. According to the industry distribution chart, Gerresheimer AG ranks #236 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 28.9%.
Is Gerresheimer AG's EBITDA Margin % too high?
Gerresheimer AG's current EBITDA Margin % of 13.38% is 36% below median its 10-year median of 20.77. Over the past 10 years, this metric has ranged from a low of 17.59 to a high of 28.21. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Gerresheimer AG's value of 13.38% is 79% above this industry median. Based on the distribution chart, Gerresheimer AG ranks #236 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gerresheimer AG has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #236 out of 816 companies for EBITDA Margin %. This puts Gerresheimer AG in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Gerresheimer AG's value of 13.38% is 79% above this benchmark. Historically, Gerresheimer AG's own EBITDA Margin % has ranged from 17.59 to 28.21 over the past decade. While the company's 10-year median is 20.77 vs. the industry median of 7.48, Gerresheimer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gerresheimer AG's current EBITDA Margin % of 13.38% is 79% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gerresheimer AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current EBITDA Margin % is 13.38%, which is 36% below median its own 10-year median of 20.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (HAM:GXI) is currently considered Possible Value Trap. The stock's GF Value™ is €99.85, compared to a current price of €26.34 — trading 73.6% below its estimated fair value. The current EBITDA Margin % is 13.38%, which is 36% below median its 10-year median of 20.77 and 79% above the Medical Devices & Instruments industry median of 7.48. Gerresheimer AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gerresheimer AG (HAM:GXI), the current EBITDA Margin % is 13.38% as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (HAM:GXI) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of €26.34 is trading 73.6% below its estimated GF Value™ of €99.85.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for HAM:GXI:
EBITDA Margin %: 13.38% (36% below median its 10-year median of 20.77)
GF Value™: €99.85 vs. price of €26.34 (73.6% below fair value)
Industry Position: 79% above the Medical Devices & Instruments median (#236 of 816)
No single metric tells the full story. See the HAM:GXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
64GF Score
Get the complete analysis for HAM:GXI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:GXI has been successfully added to your 
